Regeneron Pharmaceuticals, Inc.
807.65USD
-2.6600 (-0.33%)
Computing valuation metrics…
Valuation
P/E (TTM)
19.27x
P/E (Forward)
13.37x
EV/EBITDA
17.30x
EV/Revenue
4.87x
P/S (TTM)
5.37x
P/B
2.63x
FCF Yield
4.51%
Dividend Yield
0.45%
Gross Margin
37.68%
Operating Margin
24.74%
Net Margin
27.86%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals, Inc. | $83.43B | 19.27x | 17.30x | 4.51% | 16.73% | 0.45% |
| VRTXVertex Pharmaceuticals Incorporated | $132.08B | 30.32x | 25.13x | 1.99% | 12.50% | — |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $62.33B |
| 38.24x |
| 968.98x |
| 1.22% |
| 59.30% |
| — |
| MRNAModerna, Inc. | $54.14B | — | — | 0.55% | 2.10% | — |
| RPRXRoyalty Pharma plc | $35.01B | 32.58x | 24.44x | -3.41% | 16.50% | 1.47% |
| ROIVRoivant Sciences Ltd. | $30.20B | — | — | -3.73% | -33.50% | — |
| INCYIncyte Corporation | $25.22B | 15.85x | 10.67x | 4.68% | 37.70% | — |
| BNTXBioNTech SE | $24.65B | — | — | -1.01% | -59.50% | — |
| ASNDAscendis Pharma A/S | $17.11B | 20.08x | 63.64x | 0.07% | 114.70% | — |